Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Effects of nicotinamide adenine dinucleotide hydride on physical and mental performance.

Mero A, Raitanen R, Birkmayer J, Komi P.

J Sports Sci. 2008 Feb 1;26(3):311-9.

PMID:
18074300
2.

On the safety of reduced nicotinamide adenine dinucleotide (NADH).

Birkmayer JG, Nadlinger KF, Hallström S.

J Environ Pathol Toxicol Oncol. 2004;23(3):179-94.

PMID:
15312041
3.

NADH supplementation decreases pinacidil-primed I K ATP in ventricular cardiomyocytes by increasing intracellular ATP.

Pelzmann B, Hallström S, Schaffer P, Lang P, Nadlinger K, Birkmayer GD, Vrecko K, Reibnegger G, Koidl B.

Br J Pharmacol. 2003 Jun;139(4):749-54.

5.

Extracellular metabolisation of NADH by blood cells correlates with intracellular ATP levels.

Nadlinger K, Westerthaler W, Storga-Tomic D, Birkmayer JG.

Biochim Biophys Acta. 2002 Nov 14;1573(2):177-82.

PMID:
12399028
6.

[Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit].

Birkmayer GD, Kay GG, Vürre E.

Wien Med Wochenschr. 2002;152(17-18):450-4. German.

PMID:
12385067
7.

Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes.

Nadlinger K, Birkmayer J, Gebauer F, Kunze R.

Neuroimmunomodulation. 2001;9(4):203-8.

PMID:
11847482
8.

Effect of extracellular NADH on human tumor cell proliferation.

Slade N, Storga-Tomic D, Birkmayer GD, Pavelic K, Pavelic J.

Anticancer Res. 1999 Nov-Dec;19(6B):5355-60.

PMID:
10697561
9.

Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.

Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA.

Ann Allergy Asthma Immunol. 1999 Feb;82(2):185-91.

PMID:
10071523
10.

Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR).

Bushehri N, Jarrell ST, Lieberman S, Mirdamadi-Zonozi N, Birkmayer G, Preuss HG.

Geriatr Nephrol Urol. 1998;8(2):95-100.

PMID:
9893217
11.

NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells.

Vrecko K, Storga D, Birkmayer JG, Möller R, Tafeit E, Horejsi R, Reibnegger G.

Biochim Biophys Acta. 1997 Jul 10;1361(1):59-65.

12.
13.

Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH).

Vrecko K, Birkmayer JG, Krainz J.

J Neural Transm Park Dis Dement Sect. 1993;5(2):147-56.

PMID:
8101444
14.
15.

The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients.

Birkmayer W, Birkmayer JG, Vrecko K, Paletta B.

Adv Neurol. 1990;53:545-9. No abstract available.

PMID:
2239495
16.

Strategy and tactic of modern Parkinson therapy.

Birkmayer W, Birkmayer GJ.

Acta Neurol Scand Suppl. 1989;126:63-6. Review.

PMID:
2694735
17.

Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.

Birkmayer W, Birkmayer GJ.

Ann Clin Lab Sci. 1989 Jan-Feb;19(1):38-43.

PMID:
2644889
19.

The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.

Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E.

J Neural Transm Park Dis Dement Sect. 1989;1(4):297-302.

PMID:
2597315
20.

The importance of monoamine metabolism for the pathology of the extrapyramidal system.

Birkmayer W.

J Neurovisc Relat. 1969;31:Suppl 9:297+. Review. No abstract available.

PMID:
4319516

Supplemental Content

Loading ...
Support Center